Skip to Content

GLP-1 medications and public health

Calendar icon Health and Care

Folder icon Jul 2026 - Ongoing

GLP-1 medications have emerged as one of the most significant developments in obesity treatment in recent decades. Their rapidly expanding use has generated considerable public interest and debate, raising important questions about their implications for population health, health inequalities, healthcare systems and wider society.

Evidence demonstrates that these medications can achieve substantial weight loss and improve health outcomes for people living with obesity. However, their growing availability, including through private prescribing and online services, presents new challenges around equitable access, long-term sustainability, affordability and appropriate use. Their wider implications extend beyond clinical treatment, potentially influencing approaches to prevention, health improvement, food environments and public health policy.

As the evidence and policy landscape continue to evolve, there is an important opportunity to examine how GLP-1 medications might contribute to improving population health while ensuring that their benefits are realised fairly across society. GCPH's work in this area seeks to strengthen understanding of these emerging issues and support informed, evidence-based approaches to policy and practice in Glasgow, Scotland and beyond.

objectives icon Project objectives

GCPH's work on GLP-1 medications has four key aims:

  1. To strengthen understanding of the wider public health, social and health inequalities implications of GLP-1 medications, extending beyond their clinical effectiveness in obesity treatment.
  2. To critically examine emerging research, data and policy developments, identifying opportunities, uncertainties and evidence gaps relevant to population health and prevention.
  3. To explore how access to, and use of, GLP-1 medications may influence existing health inequalities, including the role of socioeconomic circumstances, healthcare access and wider structural determinants of health.
  4. To generate accessible, balanced and actionable evidence that supports public health policy, service planning and informed discussion, while encouraging collaboration across research, policy, practice and communities.

involved icon What is involved

This work brings together evidence synthesis, public health analysis, policy review and engagement with relevant stakeholders to explore the expanding role of GLP-1 medications in society.

An initial scoping review examines the available evidence through ten critical questions, considering clinical effectiveness, prevention, safety, sustainability, cost-effectiveness, health inequalities, prescribing practices and wider implications for health systems and public health policy.

Building on this foundation, GCPH aims to contribute to wider discussions about the evolving use of these medications, including their potential to improve population health, their relationship with existing approaches to obesity prevention and treatment, and the importance of equitable access.

The work also recognises the value of interdisciplinary perspectives and lived experience in understanding how these medications are accessed, used and experienced across different population groups.

findings icon Findings & outcomes

Emerging evidence indicates that GLP-1 medications offer considerable potential to improve health outcomes and contribute to addressing obesity-related ill health. However, their wider population-level impacts remain uncertain, particularly in relation to long-term use, affordability, health inequalities and implications for prevention and healthcare systems.

Access to treatment is an important consideration. Differences in eligibility, affordability, health literacy and access to healthcare may influence who benefits from these developments, with the potential to reinforce existing inequalities if equity is not considered from the outset.

This work highlights the importance of viewing GLP-1 medications within a broader public health context, recognising that effective obesity treatment must sit alongside continued action on the social, economic, environmental and commercial determinants of health.

Through ongoing research, analysis and knowledge exchange, GCPH aims to contribute to a more informed and proportionate understanding of GLP-1 medications, supporting policies and approaches that maximise their potential benefits while promoting fairness, prevention and population health.

arrow left Previous

Minimum Income and Cost of Living Research in Castlemilk (MICoL)

Back to

Our work